Savoxepine versus haloperidol: Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia

European Archives of Psychiatry and Clinical Neuroscience

Volumn 252, Issue 2, 2002, Pages 76-80

  Volz, Hans Peter ^a,b   Möller, Hans Jürgen ^c   Gerebtzoff, Alexandre ^d   Bischoff, Serge ^d  

^a Krankenhaus fur Psychiatrie   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atypical neuroleptic; Controlled clinical trial; Pharmacokinetic; Savoxepine

Indexed keywords

BIPERIDEN; HALOPERIDOL; SAVOXEPINE;

AKATHISIA; ARTICLE; CATALEPSY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SCHIZOPHRENIA; TITRIMETRY; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; DIBENZOXAZEPINES; DOUBLE-BLIND METHOD; DRUG TOLERANCE; HALOPERIDOL; HUMANS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 0036924681     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-002-0364-7     Document Type: Article

References (19)

1. Bischoff S (1992) Towards the understanding of the neuroanatomical substrate of schizophrenia: the contribution of savoxepine. In: Meltzer HY (ed) Novel Antipsychotic Drugs. Raven Press, New York, pp 117-134
2. Bischoff S, Christen P, Vassout A (1988) Blockade of hippocampal dopamine (DA) receptors: a tool for antipsychotics with low extrapyramidal side effects. Prog Neuropsychopharmacol Biol Psychiatry 12:455-467
3. Bischoff S, Vassout A, Waldmeier P (1986) The dopaminergic system in the hippocampus: site of action for antipsychotic activity of neuroleptics? In: Woodruff GN, Poat JA, Roberts PJ (eds) Dopaminergic Systems and Their Regulation. VCH Publishers, Weinheim, pp 397-398
4. Butler B, Bech P (1987) Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report. Pharmacopsychiatry 20:122-126
5. Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, Pappas N, Brodie JD, Ashby CR Jr. (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15:821-829
6. Dixon LB, Lehman AF, Levine J (1995) Conventional antipsychotic medications for schizophrenia. Schizophr Bull 21:567-577
7. Farde L, Wiesel FA, Nordström AL, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99 (Suppl):S28-S31
8. Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120:128-133
9. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 158:360-369
10. Lavin MR, Rifkin A (1992) Neuroleptic-induced parkinsonism. In: Kane JN, Lieberman JA (eds) Adverse Effects of Psychotropic Drugs. Guilford, New York, pp 175-188
11. Leenders KL, Antonini A, Thomann R, Locher JT, Maitre L, Gerebtzoff A, Beer HF, Ametamey S, Weinreich R, Gut A, Gnirss F, Ofner S, Schilling W, Waldmeier PC (1993) Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). Eur J Clin Pharmacol 44:135-140
12. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246
13. Möller HJ, Kissling W, Dietzfelbinger T, Stoll KD, Wendt G (1989) Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study. Pharmacopsychiatry 22:38-41
14. Petit M, Raniwalla J, Tweed J, Leutenegger E, Dollfus S, Kelly F (1996) A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 32:81-87
15. Snyder SH (1990) Pharmacology. The dopamine connection [news]. Nature 347 (6289):121-122
16. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350 (6319):610-614
17. Waldmeier PC, Bischoff S, Bittiger H, Hauser K, Vassout A, Delini-Stula A, Haeusler A, Schenkel L, Storni A (1986) Pharmacological profiles of four new tetracyclic dopamine antagonists, maroxepine, citatepine, eresepine, and cipazoxepine. Pharmacopsychiatry 19:316-317
18. Wetzel H, Wiedemann K, Holsboer F, Benkert O (1991) Savoxepine: invalidation of an atypical neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients. Psychopharmacology 103:280-283
19. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc'h C, Marzière B, Paillère-Martinot ML (2001) Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipychotic drugs in patients with schizophrenia. Br J Psychiatry 179:503-508